Page last updated: 2024-11-05

thalidomide and Obesity

thalidomide has been researched along with Obesity in 10 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for psoriasis treatment."7.88Apremilast in psoriasis - a prospective real-world study. ( Herman, R; Monshi, B; Posch, C; Rappersberger, K; Richter, L; Sanlorenzo, M; Vujic, I, 2018)
"Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for psoriasis treatment."3.88Apremilast in psoriasis - a prospective real-world study. ( Herman, R; Monshi, B; Posch, C; Rappersberger, K; Richter, L; Sanlorenzo, M; Vujic, I, 2018)
"Lenalidomide (Revlimid; Selleck Chemicals, Houston, TX, USA), an analogue of thalidomide, possesses potent cytokine modulatory capacity through inhibition of cytokines such as tumour necrosis factor (TNF)-α, a cytokine pivotal for the onset and development of complications in obesity and diabetes mellitus."3.80Tumour necrosis factor-α inhibition with lenalidomide alleviates tissue oxidative injury and apoptosis in ob/ob obese mice. ( Dong, H; Hu, N; Jiang, S; Jones, KR; Kang, YM; Luo, F; Ren, J; Xiong, L; Zhu, X; Zou, Y, 2014)
"Lenalidomide is a potent immunomodulatory agent capable of downregulating proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) and upregulating anti-inflammatory cytokines."1.38Short-term lenalidomide (Revlimid) administration ameliorates cardiomyocyte contractile dysfunction in ob/ob obese mice. ( Dong, M; Hua, Y; Jones, KR; Li, L; Li, Q; Ren, J; Smith, DT; Yuan, M, 2012)
"Thalidomide-treated animals received thalidomide i."1.36The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice. ( Bartchewsky, W; Carvalho, Pde O; Cintra, DE; Compri, CM; Fornari, JV; Gambero, A; Pedrazzoli, J; Pinto, Lde F; Ribeiro, ML; Saad, MJ; Trevisan, M; Velloso, LA, 2010)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's7 (70.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Kalisch-Smith, JI1
Ved, N1
Sparrow, DB1
Vujic, I1
Herman, R1
Sanlorenzo, M1
Posch, C1
Monshi, B1
Rappersberger, K1
Richter, L1
Winiczenko, R1
Górnicki, K1
Kaleta, A1
Janaszek-Mańkowska, M1
Khan, ZA1
Singh, C1
Khan, T1
Ganguly, M1
Bradsher, C1
Goodwin, P1
Petty, JT1
Sandau, C1
Bove, DG1
Marsaa, K1
Bekkelund, CS1
Lindholm, MG1
Salazar, J1
Bermúdez, V1
Olivar, LC1
Torres, W1
Palmar, J1
Añez, R1
Ordoñez, MG1
Rivas, JR1
Martínez, MS1
Hernández, JD1
Graterol, M1
Rojas, J1
Mubarak, Z1
Humaira, A1
Gani, BA1
Muchlisin, ZA1
Gremillet, C1
Jakobsson, JG1
Gomila, A1
Shaw, E1
Carratalà, J1
Leibovici, L1
Tebé, C1
Wiegand, I1
Vallejo-Torres, L1
Vigo, JM1
Morris, S1
Stoddart, M1
Grier, S1
Vank, C1
Cuperus, N1
Van den Heuvel, L1
Eliakim-Raz, N1
Vuong, C1
MacGowan, A1
Addy, I1
Pujol, M1
Cobb, A1
Rieger, E1
Bell, J1
Mallik, S1
Zhao, Z1
Szécsényi, Á1
Li, G1
Gascon, J1
Pidko, EA1
Zhang, GR1
Wolker, T1
Sandbeck, DJS1
Munoz, M1
Mayrhofer, KJJ1
Cherevko, S1
Etzold, BJM1
Lukashuk, L1
Yigit, N1
Rameshan, R1
Kolar, E1
Teschner, D1
Hävecker, M1
Knop-Gericke, A1
Schlögl, R1
Föttinger, K1
Rupprechter, G1
Franconieri, F1
Deshayes, S1
de Boysson, H1
Trad, S1
Martin Silva, N1
Terrier, B1
Bienvenu, B1
Galateau-Sallé, F1
Emile, JF1
Johnson, AC1
Aouba, A1
Vogt, TJ1
Gevensleben, H1
Dietrich, J1
Kristiansen, G1
Bootz, F1
Landsberg, J1
Goltz, D1
Dietrich, D1
Idorn, M1
Skadborg, SK1
Kellermann, L1
Halldórsdóttir, HR1
Holmen Olofsson, G1
Met, Ö1
Thor Straten, P1
Johnson, LE1
Brockstedt, D1
Leong, M1
Lauer, P1
Theisen, E1
Sauer, JD1
McNeel, DG1
Morandi, F1
Marimpietri, D1
Horenstein, AL1
Bolzoni, M1
Toscani, D1
Costa, F1
Castella, B1
Faini, AC1
Massaia, M1
Pistoia, V1
Giuliani, N1
Malavasi, F1
Qiu, J1
Peng, S1
Yang, A1
Ma, Y1
Han, L1
Cheng, MA1
Farmer, E1
Hung, CF1
Wu, TC1
Modak, S1
Le Luduec, JB1
Cheung, IY1
Goldman, DA1
Ostrovnaya, I1
Doubrovina, E1
Basu, E1
Kushner, BH1
Kramer, K1
Roberts, SS1
O'Reilly, RJ1
Cheung, NV1
Hsu, KC1
Salgarello, T1
Giudiceandrea, A1
Calandriello, L1
Marangoni, D1
Colotto, A1
Caporossi, A1
Falsini, B1
Lefrançois, P1
Xie, P1
Wang, L2
Tetzlaff, MT1
Moreau, L1
Watters, AK1
Netchiporouk, E1
Provost, N1
Gilbert, M1
Ni, X1
Sasseville, D1
Wheeler, DA1
Duvic, M1
Litvinov, IV1
O'Connor, BJ1
Fryda, NJ1
Ranglack, DH1
Yang, Y2
Yang, J1
Zhang, X2
Grün, AL1
Emmerling, C1
Aumeeruddy-Elalfi, Z1
Ismaël, IS1
Hosenally, M1
Zengin, G1
Mahomoodally, MF1
Dotsenko, A1
Gusakov, A1
Rozhkova, A1
Sinitsyna, O1
Shashkov, I1
Sinitsyn, A1
Hong, CE1
Kim, JU1
Lee, JW1
Lee, SW1
Jo, IH1
Pandiyarajan, S1
Premasudha, P1
Kadirvelu, K1
Wang, B1
Luo, L1
Wang, D1
Ding, R1
Hong, J1
Caviezel, D1
Maissen, S1
Niess, JH1
Kiss, C1
Hruz, P1
Pockes, S1
Wifling, D1
Keller, M1
Buschauer, A1
Elz, S1
Santos, AF1
Ferreira, IP1
Pinheiro, CB1
Santos, VG1
Lopes, MTP1
Teixeira, LR1
Rocha, WR1
Rodrigues, GLS1
Beraldo, H1
Lohar, S1
Dhara, K1
Roy, P1
Sinha Babu, SP1
Chattopadhyay, P1
Sukwong, P1
Sunwoo, IY1
Lee, MJ1
Ra, CH1
Jeong, GT1
Kim, SK2
Huvinen, E1
Eriksson, JG1
Stach-Lempinen, B1
Tiitinen, A1
Koivusalo, SB1
Malhotra, M1
Suresh, S1
Garg, A1
Wei, L1
Jiang, Y2
Zhou, W1
Liu, S1
Liu, Y1
Rausch-Fan, X1
Liu, Z1
Marques, WL1
van der Woude, LN1
Luttik, MAH1
van den Broek, M1
Nijenhuis, JM1
Pronk, JT1
van Maris, AJA1
Mans, R1
Gombert, AK1
Xu, A1
Sun, J1
Li, J1
Chen, W2
Zheng, R1
Han, Z1
Ji, L1
Shen, WQ1
Bao, LP1
Hu, SF1
Gao, XJ1
Xie, YP1
Gao, XF1
Huang, WH1
Lu, X1
Gostin, PF1
Addison, O1
Morrell, AP1
Zhang, Y2
Cook, AJMC1
Liens, A1
Stoica, M1
Ignatyev, K1
Street, SR1
Wu, J1
Chiu, YL1
Davenport, AJ1
Qiu, Z1
Shu, J1
Tang, D1
Gao, X1
Zhang, J3
Huang, K1
Wai, H1
Du, K1
Anesini, J1
Kim, WS1
Eastman, A1
Micalizio, GC1
Liang, JH1
Huo, XK1
Cheng, ZB1
Sun, CP1
Zhao, JC1
Kang, XH1
Zhang, TY1
Chen, ZJ1
Yang, TM1
Wu, YY1
Deng, XP1
Zhang, YX1
Salem, HF1
Kharshoum, RM1
Abou-Taleb, HA1
AbouTaleb, HA1
AbouElhassan, KM1
Ohata, C1
Ohyama, B1
Kuwahara, F1
Katayama, E1
Nakama, T1
Kobayashi, S1
Kashiwagi, T1
Kimura, J1
Lin, JD1
Liou, MJ1
Hsu, HL1
Leong, KK1
Chen, YT1
Wang, YR1
Hung, WS1
Lee, HY1
Tsai, HJ1
Tseng, CP1
Alten, B1
Yesiltepe, M1
Bayraktar, E1
Tas, ST1
Gocmen, AY1
Kursungoz, C1
Martinez, A1
Sara, Y1
Huang, S2
Adams, E1
Van Schepdael, A1
Wang, Q1
Chung, CY1
Yang, W1
Yang, G1
Chough, S1
Chen, Y1
Yin, B1
Bhattacharya, R1
Hu, Y1
Saeui, CT1
Yarema, KJ1
Betenbaugh, MJ1
Zhang, H1
Patik, JC1
Tucker, WJ1
Curtis, BM1
Nelson, MD1
Nasirian, A1
Park, S1
Brothers, RM1
Dohlmann, TL1
Hindsø, M1
Dela, F1
Helge, JW1
Larsen, S1
Gayani, B1
Dilhari, A1
Wijesinghe, GK1
Kumarage, S1
Abayaweera, G1
Samarakoon, SR1
Perera, IC1
Kottegoda, N1
Weerasekera, MM1
Nardi, MV1
Timpel, M1
Ligorio, G1
Zorn Morales, N1
Chiappini, A1
Toccoli, T1
Verucchi, R1
Ceccato, R1
Pasquali, L1
List-Kratochvil, EJW1
Quaranta, A1
Dirè, S1
Heo, K1
Jo, SH1
Shim, J1
Kang, DH1
Kim, JH1
Park, JH1
Akhtar, N1
Saha, A1
Kumar, V1
Pradhan, N1
Panda, S1
Morla, S1
Kumar, S1
Manna, D1
Wang, H1
Xu, E1
Yu, S1
Li, D1
Quan, J1
Xu, L1
Saslow, SA1
Um, W1
Pearce, CI1
Bowden, ME1
Engelhard, MH1
Lukens, WL1
Kim, DS1
Schweiger, MJ1
Kruger, AA1
Adair, LS1
Kuzawa, C1
McDade, T1
Carba, DB1
Borja, JB1
Liang, X2
Song, W1
Wang, K1
Zhang, B1
Peele, ME1
Luo, HR1
Chen, ZY1
Fei, JJ1
Du, ZJ1
Yi, KJ1
Im, WT1
Kim, DW1
Ji, X1
Zhang, C1
Xu, Z1
Ding, Y1
Song, Q1
Li, B2
Zhao, H1
Lee, DW1
Lee, H1
Kwon, BO1
Khim, JS1
Yim, UH1
Park, H1
Park, B1
Choi, IG1
Kim, BS1
Kim, JJ1
Wang, JJ1
Chen, Q1
Li, YZ1
Sakai, M1
Yamaguchi, M1
Nagao, Y1
Kawachi, N1
Kikuchi, M1
Torikai, K1
Kamiya, T1
Takeda, S1
Watanabe, S1
Takahashi, T1
Arakawa, K1
Nakano, T1
Rufo, S1
Continentino, MA1
Nikolaou, V1
Plass, F1
Planchat, A1
Charisiadis, A1
Charalambidis, G1
Angaridis, PA1
Kahnt, A1
Odobel, F1
Coutsolelos, AG1
Fuentes, I1
García-Mendiola, T1
Sato, S1
Pita, M1
Nakamura, H1
Lorenzo, E1
Teixidor, F1
Marques, F1
Viñas, C1
Liu, F1
Qi, P1
Zhang, L1
Kmietowicz, Z1
Zhu, X1
Jiang, S1
Hu, N1
Luo, F1
Dong, H1
Kang, YM1
Jones, KR2
Zou, Y1
Xiong, L1
Ren, J2
Nakamitsu, PZ1
Compri, CM2
de Fraia Pinto, L1
Gotardo, ÉM1
de Oliveira, CC1
Ribeiro, ML2
Pedrazzoli, J2
Gambero, A2
Pinto, Lde F1
Fornari, JV1
Bartchewsky, W1
Cintra, DE1
Trevisan, M1
Carvalho, Pde O1
Velloso, LA1
Saad, MJ1
Li, L1
Hua, Y1
Dong, M1
Li, Q1
Smith, DT1
Yuan, M1
Rupnick, MA1
Panigrahy, D1
Zhang, CY1
Dallabrida, SM1
Lowell, BB1
Langer, R1
Folkman, MJ1
Chowta, MN1
Chowta, NK1

Reviews

1 review available for thalidomide and Obesity

ArticleYear
Environmental Risk Factors for Congenital Heart Disease.
    Cold Spring Harbor perspectives in biology, 2020, 03-02, Volume: 12, Issue:3

    Topics: Alcohol Drinking; Animals; Diabetes Mellitus; Environmental Exposure; Gene-Environment Interaction;

2020

Trials

1 trial available for thalidomide and Obesity

ArticleYear
    Neural computing & applications, 2018, Volume: 30, Issue:6

    Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosp

2018

Other Studies

8 other studies available for thalidomide and Obesity

ArticleYear
Apremilast in psoriasis - a prospective real-world study.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2018, Volume: 32, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Body Weight; Diarrhea; Drug Substi

2018
More drug studies need to include pregnant women, says bulletin.
    BMJ (Clinical research ed.), 2013, Jun-14, Volume: 346

    Topics: Anticonvulsants; Clinical Trials as Topic; Drug Industry; Female; Humans; Hypnotics and Sedatives; M

2013
Tumour necrosis factor-α inhibition with lenalidomide alleviates tissue oxidative injury and apoptosis in ob/ob obese mice.
    Clinical and experimental pharmacology & physiology, 2014, Volume: 41, Issue:7

    Topics: Animals; Apoptosis; Blood Glucose; Gene Expression Regulation; Glucose; Immunologic Factors; Intesti

2014
Thalidomide controls adipose tissue inflammation associated with high-fat diet-induced obesity in mice.
    Endocrine, metabolic & immune disorders drug targets, 2015, Volume: 15, Issue:2

    Topics: 3T3-L1 Cells; Adipogenesis; Adipokines; Adipose Tissue; Adiposity; Animals; Anti-Inflammatory Agents

2015
The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:4

    Topics: Animals; Biopsy, Needle; Blood Glucose; Diet; Dietary Fats; Disease Models, Animal; Fatty Liver; Imm

2010
Short-term lenalidomide (Revlimid) administration ameliorates cardiomyocyte contractile dysfunction in ob/ob obese mice.
    Obesity (Silver Spring, Md.), 2012, Volume: 20, Issue:11

    Topics: Absorptiometry, Photon; Animals; Blotting, Western; Caspases, Effector; Cells, Cultured; Endoplasmic

2012
Adipose tissue mass can be regulated through the vasculature.
    Proceedings of the National Academy of Sciences of the United States of America, 2002, Aug-06, Volume: 99, Issue:16

    Topics: Adipose Tissue; Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Biphenyl Comp

2002
Hypothyroidism caused by thalidomide.
    Indian journal of medical sciences, 2006, Volume: 60, Issue:10

    Topics: Adult; Angiogenesis Inhibitors; Female; Humans; Hypothyroidism; Multiple Myeloma; Obesity; Thalidomi

2006